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Despite a wealth of preclinical studies, it is unclear
whetherPIK3CA or phosphatase and tensin homolog
(PTEN) gene aberrations are actionable in the clinical
setting. Of 1,656 patients with advanced, refractory
cancers tested for PIK3CA or PTEN abnormalities,
PIK3CA mutations were found in 9% (146/1,589),
and PTEN loss and/or mutation was found in 13%
(149/1,157). In multicovariable analysis, treatment
with a phosphatidylinositol 3-kinase (PI3K)/AKT/
mammalian target of rapamycin (mTOR) inhibitor
was the only independent factor predicting response
to therapy in individuals harboring a PIK3CA or PTEN
aberration. The rate of stable disease R6 months/
partial response reached 45% in a subgroup of
individuals with H1047R PIK3CA mutations. Aberra-
tions in the PI3K/AKT/mTOR pathway are common
and potentially actionable in patients with diverse
advanced cancers. This work provides further impor-
tant clinical validation for continued and accelerated
use of biomarker-driven trials incorporating rational
drug combinations.
INTRODUCTION
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target
of rapamycin (mTOR) pathway is frequently activated in many
human cancers, often via molecular abnormalities such as
PIK3CA mutations or loss of phosphatase and tensin homolog
(PTEN) function (Engelman, 2009; Hollander et al., 2011; Sam-
uels et al., 2004). Preclinical models and early clinical data in
several tumor types suggested that PIK3CA mutations and
loss of PTEN function can result in increased sensitivity to
therapies targeting the PI3K/AKT/mTOR signaling pathwayC(Di Nicolantonio et al., 2010; Engelman et al., 2008; Ihle et al.,
2009; Janku et al., 2011b; Moroney et al., 2011; Ni et al.,
2012; Tsimberidou et al., 2012; Wee et al., 2008; Weigelt
et al., 2011).
Patients with gynecological and breast tumors and PIK3CA
mutations demonstrated a partial response (PR) rate of 30%
in early-phase clinical trials with PI3K/AKT/mTOR inhibitors
compared to 10% in patients without PIK3CA mutations
(Janku et al., 2012b). It is conceivable that loss of PTEN func-
tion, which is a major negative regulator of the pathway, can
be similarly predictive, whereas simultaneous mutations in
the mitogen-activated protein kinase (MAPK) pathway might
lead to therapeutic resistance (Di Nicolantonio et al., 2010;
Engelman et al., 2008; Ihle et al., 2009; Tsimberidou et al.,
2012).
Identifying actionable molecular aberrations has been critical
to several major therapeutic advances in cancer medicine.
Examples include BCR-ABL fusion in chronic myeloid leukemia
(CML), epidermal growth factor (EGFR) mutations and EML4-
ALK fusion in non-small-cell lung cancer, and BRAF mutations
in melanoma (Druker et al., 2001; Falchook et al., 2012; Flaherty
et al., 2010; Lynch et al., 2004). Therefore, we investigated the
relationship among PIK3CA mutations and PTEN aberrations
and treatment outcomes in patients with advanced cancer who
were referred to the Clinical Center for Targeted Therapy at
The University of Texas MD Anderson Cancer Center (MD
Anderson).RESULTS
Patients
A total of 1,656 patients with diverse advanced cancers
were analyzed for the presence of PIK3CA mutations and/
or PTEN aberrations (Table 1). Their median age was 59
years (range, 13–92 years) and most patients (1,288; 77%)
were white. The most common tumor types were colorectalell Reports 6, 377–387, January 30, 2014 ª2014 The Authors 377
Table 1. Patient Characteristics
Variable PIK3CA Mutation (%) Wild-Type PIK3CA (%) p Value PTEN Aberration (%) PTEN Intact (%) p Value
All 160 (100)a,b 1,429 (100)a NA 163 (100)b,c 994 (100)c NA
Gender
Men 62 (39) 683 (48) 0.03 86 (53) 478 (48) 0.27
Women 98 (61) 746 (52) 77 (47) 516 (52)
Median age, range (years) 56, 16–83 59, 13–92 0.16 59, 20–83 59, 14–90 0.74
Ethnicity
White 126 (79) 1,115 (78) 0.97 133 (82) 768 (77) 0.34
African-American 14 (9) 127 (9) 13 (8) 86 (9)
Hispanic 11 (7) 112 (8) 7 (4) 90 (9)
Asian 7 (4) 52 (3.5) 7 (4) 34 (3)
Other 2 (1) 23 (1.5) 3 (2) 16 (2)
Tumor type
Colorectal 46 (29) 236 (17) NA 28 (17) 174 (18) NA
Ovarian 16 (10) 163 (11) 5 (3) 125 (13)
Melanoma 2 (1) 120 (8) 12 (7) 61 (6)
Head and neck: squamous 13 (8) 82 (6) 10 (6) 67 (7)
Soft tissue sarcomas 2 (1) 97 (7) 5 (3) 74 (7)
Non-small-cell lung 6 (4) 83 (6) 15 (9) 49 (5)
Breast 21 (13) 57 (4) 9 (6) 43 (4)
Uterine 16 (10) 50 (3) 15 (9) 34 (3)
Thyroid 3 (2) 41 (3) 3 (2) 24 (2)
Pancreatic 1 (<1) 39 (3) 5 (3) 23 (2)
Gastric 2 (1) 37 (3) 1 (<1) 28 (3)
Neuroendocrine 2 (1) 36 (3) 2 (1) 30 (3)
Prostate 1 (<1) 35 (2) 8 (5) 29 (3)
Renal 3 (2) 33 (2) 10 (6) 13 (1)
Salivary gland 1 (<1) 33 (2) 3 (2) 26 (3)
Cervical: squamous 10 (6) 23 (2) 3 (2) 21 (2)
Biliary tract 0 (0) 27 (2) 2 (1) 20 (2)
Hepatocellular 0 (0) 27 (2) 6 (4) 16 (2)
Bladder and urothelial 3 (2) 16 (1) 3 (2) 9 (<1)
Head and neck: nonsquamous 3 (2) 16 (1) 0 (0) 13 (1)
Cervical: adenocarcinoma 1 (<1) 18 (1) 3 (2) 9 (<1)
Unknown primary 2 (1) 16 (1) 2 (1) 13 (1)
Ewing 0 (0) 15 (1) 1 < 1) 11 (1)
Small cell lung 0 (0) 15 (1) 3 (2) 7 (<1)
Esophageal: adenocarcinoma 0 (0) 13 (<1) 2 (1) 10 (1)
Other 6 (4) 101 (7) 7 (4) 65 (7)
NA, not applicable. n = 1,656.
aPIK3CA mutations were tested in 1,589 patients.
bPatients with simultaneous PIK3CA mutations and PTEN aberrations are included.
cPTEN aberrations were tested in 1,157 patients.cancer (298; 18%), ovarian cancer (184; 11%), and mela-
noma (126; 8%).
PIK3CA Mutations and PTEN Aberrations
Of the 1,656 patients, 1,589 were tested for PIK3CA mutations,
1,157 for PTEN aberrations, and 1,090 for both PIK3CA muta-
tions and PTEN aberrations. PIK3CA mutations were detected378 Cell Reports 6, 377–387, January 30, 2014 ª2014 The Authorsin 9% (146/1,589) of patients, PTEN aberrations in 13% (149/
1,157), and simultaneous PIK3CA mutations and PTEN aberra-
tions in 1% (14/1,090). When analyzing 1,090 patients who
were tested for both PIK3CA mutations and PTEN aberrations,
89 (8%) had PIK3CA mutations, 134 (12%) had PTEN aberra-
tions, and 14 (1%) had simultaneous PIK3CA mutations and
PTEN aberrations (Figure 1).
Figure 1. PIK3CA Mutations and PTEN Aberrations
Proportion of PIK3CA mutations and PTEN aberrations in 1,090 patients who
had both PIK3CA and PTEN testing.
Figure 2. PIK3CA and KRAS Mutations
PIK3CA mutations are more frequent in tumors with simultaneous KRAS
mutations (42/225, 19% versus 89/975, 9%; p < 0.001).In 160 patients with PIK3CA mutations, the most frequent
mutation was E545K (1633G > A) in 32.5% of patients (52/
160), followed by E542K (1624G > A) in 20% of patients (32/
160), and H1047R (3140A > G) in 18% of patients (29/160) (Table
S1).PIK3CAmutationswere not associatedwith age or ethnicity.
There were 163 patients with PTEN aberrations. These aberra-
tions include loss of staining on immunohistochemistry in 155
patients (1,123 tested for expression, but not for mutations),
loss of staining on immunohistochemistry in the absence of
PTEN mutations in two patients (25 tested for mutations and
expression), loss of staining on immunohistochemistry in the
presence of PTEN mutations in three patients (25 tested for
mutations and expression), PTEN mutation in the presence of
reduced staining on immunohistochemistry in one patient (25
tested for mutations and expression), or PTEN mutations in
two patients who had no immunohistochemistry performed
(nine tested for mutation only). PTEN mutations were most
frequent in exon 5 (4/6; 75%). PTEN aberrations were not asso-
ciated with gender, age, or ethnicity.
Mutations in MAPK Pathway
Of the 1,656 patients, 1,238 were tested forKRASmutations and
18% (229/1,238) were found to have mutations. The most prev-
alent were the G12D mutation (35G > A) present in 31% of
patients (72/229), G12V mutation (35G > T) in 22% (50/229),
G13D mutation (38G > A) in 10% (23/229), G12C mutation
(34G > T) in 9% (21/229), and G12A mutation (35G > C) in 8%
of patients (18/229).
Of the 1,656 patients, 618 were tested for NRAS and 5% (32/
618) were found to have mutations. The most prevalent were the
Q61K mutation (181C > A) in 25% of patients (8/32) and a Q61L
mutation (182_183AA > TG) in 12.5% of patients (4/32).
Of the 1,656 patients, 1,175 were tested forBRAF and 6% (70/
1,175) had mutations. The most prevalent were the V600Emuta-
tion (1799T > A) in 76% of patients (53/70) and a V600Kmutation
(1798_1799GT > AA) in 14% of patients (10/70).CMutations in KRAS, NRAS, and BRAF were mutually exclu-
sive, with the exception of two patients with malignant mela-
noma who had simultaneous BRAF and NRAS mutations.
Associations among PIK3CA Mutations, PTEN
Aberrations, and MAPK Mutations
PIK3CA mutations were more prevalent in patients with KRAS
mutations than wild-type (WT) KRAS (42/225, 19% versus 89/
975, 9%; p < 0.001; Figure 2). PIK3CAmutations were not asso-
ciated with NRAS or BRAF mutations.
Patients with PIK3CA Mutations or PTEN Aberrations
Treated with PI3K/AKT/mTOR Inhibitors
Response Rate
Of the 309 patients with PIK3CAmutations alone (n = 146), PTEN
aberrations (n = 149), and simultaneous PIK3CA mutations and
PTEN aberrations (n = 14), 136 patients (44%; PIK3CA muta-
tions, n = 76; PTEN aberrations, n = 51; PIK3CA mutation and
PTEN aberration, n = 9) were enrolled in studies that included
PI3K/AKT/mTOR inhibitors (Figure 3); 67 of the 309 patients
(22%) received other protocol-based experimental therapies,
often because PIK3CA/PTEN status was not available at the
time of decision making; and 106 (34%) were not treated, usually
due to ineligibility or patient/doctor preference.
When examining the 136 patients with PIK3CA and/or PTEN
aberrations treated with PI3K/AKT/mTOR axis inhibitors, we
found that these patients were refractory to a median of three
prior therapies (range, 1–12). Of these 136 patients, 25 (18%)
had colorectal cancer, 21 (15%) breast cancer, 18 (13%) endo-
metrial cancer, 14 (10%) ovarian cancer, 11 (8%) squamous
cell head and neck cancer, 8 (6%) squamous cell cervical
cancer, 7 (5%) renal cancer, 4 (3%) salivary gland cancer, 4
(3%) non-small-cell lung cancer, 3 (2%) sarcoma, and 21
(15%) other cancers (adenoid cystic head and neck cancer,
adrenocortical carcinoma, anal squamous cell cancer, appendi-
ceal carcinoma, carcinoma of unknown primary, cervical
adenocarcinoma, gastric cancer, hepatocellular carcinoma,
melanoma, Merkel cell carcinoma, neuroendocrine cancer,
pancreatic cancer, papillary thyroid cancer, urothelial carci-
noma, and small intestine cancer). Most patients (104, 76%)
received mTOR complex 1 (mTORC1) inhibitor (rapalog)-basedell Reports 6, 377–387, January 30, 2014 ª2014 The Authors 379
Figure 3. Therapies Targeting the PI3K/
AKT/mTOR Pathway
Most patients (104, 76%) received mTORC1 in-
hibitor (rapalog)-based therapy, 20 (15%) received
PI3K inhibitor-based therapy, 6 (4.5%) received
dual PI3K and mTOR kinase inhibitor-based ther-
apy, and 6 (4.5%) received AKT inhibitor-based
therapy.therapy; 20 (15%) received PI3K inhibitor-based therapy; 6
(4.5%) received dual PI3K and mTOR kinase inhibitor-based
therapy; and 6 (4.5%) received AKT inhibitor-based therapy (Fig-
ure 3). Single-agent therapies were given to 41 (30%) of patients
and 95 (70%) received combination therapy (Table S2). Combi-
nation therapies that included chemotherapy were administered
to 49 patients (36%), and a combination of targeted therapies
were administered to 46 patients (34%). Of note, 7 (5%) patients
received combinations simultaneously targeting the PI3K/AKT/
mTOR and MAPK pathways. Overall, 25 patients (18%, 95%
confidence interval [CI] 0.13–0.26; Table S3) achieved a PR
(defined in the Experimental Procedures) (Figure 4) and an
additional nine (7%, 95% CI 0.04–0.12) had stable disease
(SD) R 6 months (rate of SD R 6 months/PR 25%, 34/136,
95% CI 0.18–0.33). The observed PR rate compared favorably
to a complete response [CR]/PR rate of 6% (26/458; 95% CI
0.04–0.08; p < 0.001) in 458 patients without known PIK3CA
mutations and/or PTEN aberrations treated on the same PI3K/
AKT/mTOR protocols (Table S4).
Of the 67 patients with PIK3CA mutations and/or PTEN aber-
rations who received protocol-based experimental therapies
other than PI3K/AKT/mTOR inhibitors, only three (4%, 95% CI
0.02–0.12) attained a PR, which was significantly inferior
compared to 25 (18%) PRs in 136 patients treated with PI3K/
AKT/mTOR inhibitors (p = 0.008; Table S4). An additional anal-
ysis, which excluded patients with colorectal cancer, showed
that of the 52 patients with PIK3CA mutations and/or PTEN
aberrations who received protocol-based experimental thera-
pies other than PI3K/AKT/mTOR inhibitors, only three (6%,
95% CI 0.02–0.16) attained a PR, which was significantly inferior
compared to 25 PRs (23%, 95% CI 0.16–0.31) in 111 patients
treated with PI3K/AKT/mTOR inhibitors (p = 0.007). In addition,
we have shown that patients with breast and gynecological380 Cell Reports 6, 377–387, January 30, 2014 ª2014 The Authorsmalignancies and PIK3CA mutations
can benefit from therapies that include
PI3K/AKT/mTOR inhibitors (Janku et al.,
2012b). Therefore, we performed an anal-
ysis, which excluded patients with gyne-
cological cancers (ovarian, cervical, and
uterine), breast cancers, and colorectal
cancers, and demonstrated that of the
45 patients with PIK3CA mutations and/
or PTEN aberrations who received proto-
col-based experimental therapies other
than PI3K/AKT/mTOR inhibitors, three
(7%, 95% CI 0.02–0.18) attained a PR,
compared to eight PRs (17%, 95% CI
0.09–0.30) in 47 patients treated withPI3K/AKT/mTOR inhibitors (p = 0.20). Furthermore, we per-
formed an additional analysis on 104 patients with PIK3CA mu-
tations and/or PTEN aberrations, who received treatment with
mTORC1 inhibitors (rapalogs). Of these 104 patients, 22 (21%,
95% CI 0.14–0.30) had a PR compared to three PRs (4%, 95%
CI 0.02–0.12) in 67 patients with PIK3CA mutations and/or
PTEN aberrations who received protocol-based experimental
therapies other than PI3K/AKT/mTOR inhibitors (p = 0.003).
There was no difference among patients with PIK3CA
mutations, PTEN aberrations, or both PIK3CA mutations and
PTEN aberrations in the rate of PR (14/76, 18% versus 10/51,
20% versus 1/9, 11%; p = 0.83) and SD R 6 months/PR (19/
76, 25% versus 14/51, 27% versus 1/9, 11%; p = 0.58) on
PI3K/AKT/mTOR inhibitors.
Of 136 patients with PIK3CA mutations and/or PTEN aberra-
tions treated with PI3K/AKT/mTOR inhibitors, there was no PR
and only one (4%) SDR 6 months/PR in 25 patients with colo-
rectal cancer compared to 25 PRs (23%, p = 0.008) and 33
(30%, p = 0.005) SD R 6 months/PR in 111 patients with other
cancers. Also, patients treated with single-agent therapies had
lower PR rates (2/41, 5% versus 23/95, 24%; p = 0.007) and
lower rates of SD R 6 months/PR (4/41, 10% versus 30/95,
32%; p = 0.009) than patients treated with combinations. There
was no difference in PR rate in patients with three or fewer prior
therapies compared to more than three prior therapies (18/80,
23% versus 7/56, 13%; p = 0.18); however, patients with three
or fewer therapies had a higher SD R 6 months/PR rate (25/
80, 31% versus 9/56, 14%; p = 0.047).
Of the 136 treated patients with PIK3CA mutations or PTEN
aberrations, 109 (80%) had available tissue for KRAS mutation
testing. Of the 26 patients with PIK3CA mutations and/or PTEN
aberrations and simultaneous KRAS mutations in codon 12 or
13, only one (4%) had a PR, compared to 20 PRs (24%) in 83
Figure 4. Waterfall Plot Shows Best
Response for Patients with PIK3CA Muta-
tions or PTEN Aberrations Treated with
PI3K/AKT/mTOR Inhibitors
Of the 136 treated patients, 135 are depicted in the
waterfall plot (one patient died of unrelated causes
prior to her first restaging). A total of 25 PRs and
33 minor regressions less than PR were observed.
The overall PR rate was 18%.patients with PIK3CA mutations and/or PTEN aberrations
without KRAS codon 12 or 13 mutations (p = 0.023). Similarly,
only one (4%) patient with PIK3CA mutations and/or PTEN
aberrations and simultaneous KRAS mutations in codon 12 or
13 had SD R 6 months/PR compared to 27 (33%) SD R
6 months/PR in 83 patients with PIK3CA mutations and/or
PTEN aberrations without KRAS codon 12 or 13 mutations (p =
0.004).
In 85 patients with PIK3CA mutations treated with PI3K/AKT/
mTOR inhibitors, there were seven PRs (35%) and nine (45%)
SD R 6 months/PR in 20 patients with H1047R mutations
compared to eight PRs (12%, p = 0.039) and 11 (17%) SD R
6 months/PR in 65 patients with other PIK3CA mutations (p =
0.016).
Multicovariate Analysis
We created a multicovariate logistic regression model for 203
patients with PIK3CAmutations and/or PTEN aberrations, which
included 136 patients treated with PI3K/AKT/mTOR inhibitors
and 67 patients treated with other protocol-based therapies.
This model included histology (colorectal versus others), type
of therapy (combination versus single agent), and treatment
with PI3K/AKT/mTOR inhibitors (yes versus no), which were
significant factors identified on univariate analysis (data not
shown). Treatment with PI3K/AKT/mTOR inhibitors was the
only independent factor predicting a PR (odds ratio [OR] 4.34,
95% CI 1.23–15.24; p = 0.02; Table 2).
In addition, a multicovariable logistic regression model within
the subgroup of patients with PIK3CA mutations or PTEN
aberrations treated with PI3K/AKT/mTOR inhibitors, which
included histology (colorectal versus others), type of therapy
(combination versus single agent), and prior therapies (up to
three versus more than three), demonstrated that treatment
with combination therapies was the only independent factor
predicting a PR with PI3K/AKT/mTOR inhibitors (OR 5.31, 95%
CI 1.16–24.25; p = 0.03) and SD R 6 months/PR (OR 4.99,
95% CI 1.39–17.89; p = 0.01; Table 3). A separate multicovari-Cell Reports 6, 377–387able logistic regression model with 109
patients having PIK3CA mutations or
PTEN aberrations treated with PI3K/
AKT/mTOR inhibitors, who were tested
for KRAS mutations, which included his-
tology (colorectal versus others), KRAS
mutation (codons 12 or 13 versus others),
type of therapy (combination versus
single agent), and prior therapies (up to
three versus more than three), showed a
trend for combination therapies (OR4.33, 95% CI 0.90–20.71; p = 0.07) predicting a PR and a trend
for combination therapies (OR 3.78, 95% CI 0.99–14.32; p =
0.05) and absence of KRAS mutation (OR 0.15, 95% CI 0.02–
1.27; p = 0.08) predicting SDR 6 months/PR.
Progression-Free Survival
The median progression-free survival (PFS) for all patients with
PIK3CA mutations and/or PTEN aberrations treated with PI3K/
AKT/mTOR inhibitors was 2.5 months (95% CI 1.8–3.2). There
was no significant difference among patients with PIK3CAmuta-
tions (n = 76), PTEN aberrations (n = 51), or both PIK3CA muta-
tions and PTEN aberrations (n = 9) in median PFS (2.3 months,
95% CI 1.7–2.9 versus 3.5 months, 95% CI 1.5–5.5 versus
2.8 months, 95% CI 0–5.7; p = 0.83).
Patients (n = 67) with PIK3CA mutations and/or PTEN aberra-
tions who received protocol-based experimental therapies other
than PI3K/AKT/mTOR inhibitors had a similar median PFS as
patients (n = 136) with PIK3CA mutations and/or PTEN aberra-
tions treatedwithPI3K/AKT/mTOR-based therapies (1.9months,
95% CI 0.9–2.9 versus 2.5 months, 95% CI 1.8–3.2; p = 0.70). In
addition, an analysis that excluded patients with colorectal
cancers showed that patients (n = 52) with PIK3CA mutations
and/or PTEN aberrations who received protocol-based experi-
mental therapies other than PI3K/AKT/mTOR inhibitors had a
similar median PFS as patients (n = 111) with PIK3CAmutations
and/or PTEN aberrations treated with PI3K/AKT/mTOR-based
therapies (2.7 months, 95% CI 0.8–4.5 versus 2.8 months,
95% CI 1.8–3.8; p = 0.93).
Patients (n = 25) with PIK3CA mutations and/or PTEN aberra-
tions and colorectal cancer treated with PI3K/AKT/mTOR
inhibitors had a shorter median PFS than patients (n = 111)
with PIK3CA mutations and/or PTEN aberrations and other
histologies (1.8 months, 95% CI 1.5–2.1 versus 2.8 months,
95% CI 1.8–3.8; p = 0.003). Patients (n = 95) with PIK3CA
mutations and/or PTEN aberrations treated with combination
therapies that included PI3K/AKT/mTOR inhibitors had a longer
median PFS than patients (n = 41) treated with single-agent, January 30, 2014 ª2014 The Authors 381
Table 2. Multicovariate Models
Outcome Measure Variable OR or HRa 95% CI p Value
PR (RECIST) colorectal cancer versus other cancers not calculatedb not calculatedb
combination therapies versus single agents 2.85 0.92–8.84 0.07
PI3K/AKT/mTOR versus other protocols 4.34 1.23–15.24 0.02
PFS more than three prior versus three or fewer prior therapies 1.22 0.88–1.71 0.24
colorectal cancer versus other cancers 1.83 1.25–2.68 0.002
combination therapies versus single agents 0.70 0.51–0.97 0.03
PI3K/AKT/mTOR versus other protocols 1.06 0.76–1.48 0.75
OS more than three prior versus three or fewer prior therapies 1.12 0.78–1.59 0.54
colorectal cancer versus other cancers 1.21 0.78–1.87 0.40
combination therapies versus single agents 0.85 0.59–1.21 0.36
PI3K/AKT/mTOR versus other protocols 1.45 0.99–2.12 0.06
Multicovariate model for response per RECIST (logistic regression), PFS (Cox regression), and OS (Cox regression) in patients (n = 203) with PIK3CA
mutations and/or PTEN aberrations treated with PI3K/AKT/mTOR inhibitors (n = 136) or other systemic-protocol-based therapies (n = 67).
aOdds ratio was calculated for response. Higher odds ratio indicates greater chance of response. Hazard ratio was calculated for progression-free and
overall survival. Higher hazard ratio indicates greater chance of progression or death.
bOR and 95% CI were not calculated because none of the patients with colorectal cancer attained a PR.PI3K/AKT/mTOR-based therapies (3.0 months, 95% CI 2.0–4.0
versus 1.8 months, 95% CI 1.6–2.0; p < 0.001; Figure 5A). There
was no difference in median PFS in patients (n = 80) with three or
fewer prior therapies compared to patients (n = 56) with more
than three prior therapies (2.5 months, 95% CI 1.8–3.2 versus
2.6 months, 95% CI 1.6–3.6; p = 0.40).
Of the 109 treated patients with PIK3CA mutations and/or
PTEN aberrations who had available tissue for KRAS mutation
testing, 26 patients with PIK3CAmutations and/or PTEN aberra-
tions and simultaneous KRASmutations in codon 12 or 13 had a
shorter median PFS compared to 83 patients without KRAS
mutations in codon 12 or 13 (1.8 months, 95% CI 1.6–2.0 versus
2.9 months, 95% CI 1.9–3.9; p = 0.004) when treated with PI3K/
AKT/mTOR inhibitors (Figure 5B).
In 85 patients with PIK3CA mutations treated with PI3K/AKT/
mTOR inhibitors, 20 patients with a H1047R mutation compared
to patients with other PIK3CA mutations had a longer median
PFS (4.6 months, 95% CI 0.6–8.6 versus 2 months, 1.6–2.4;
p = 0.03; Figure 5C).
Multicovariate Analysis
Similarly, we created a multicovariate Cox regression model for
203 patients with PIK3CA mutations and/or PTEN aberrations,
which included 136 patients treated with PI3K/AKT/mTOR inhib-
itors and 67 patients treated with other protocol-based thera-
pies. This model included number of prior therapies (up to three
versus more than three), histology (colorectal versus others),
type of therapy (combination versus single agent), and treatment
with PI3K/AKT/mTOR inhibitors (yes versus no) that were either
significant factors on univariate analysis (data not shown) or
were anticipated to be important. Treatment with combinations
predicted longer PFS (hazard ratio [HR] 0.70, 95% CI 0.51–
0.97; p = 0.03), while patients with colorectal cancer had a
shorter PFS (HR 1.83, 95% CI 1.25–2.68; p = 0.002; Table 2).
In addition, a multicovariable Cox regression model in patients
with PIK3CA mutations or PTEN aberrations treated with PI3K/
AKT/mTOR inhibitors, which included histology (colorectal
versus others) and type of therapy (combination versus single382 Cell Reports 6, 377–387, January 30, 2014 ª2014 The Authorsagent), demonstrated longer PFS in patients treated with com-
binations (HR 0.54, 95% CI 0.35–0.82; p = 0.004), and patients
with colorectal cancer had a trend to shorter PFS (HR 1.59,
95%CI 0.98–2.59; p = 0.06; Table 3). A separate multicovariable
Cox regression model with 109 patients with PIK3CA mutations
or PTEN aberrations treated with PI3K/AKT/mTOR inhibitors
tested for KRASmutations, which included histology (colorectal
versus others), KRAS mutation (codons 12 and 13 versus
others), and type of therapy (combination versus single agent),
showed a strong trend to longer PFS for patients treated with
combinations (HR 0.62, 95% CI 0.39–1.00; p = 0.05).
Overall Survival
The median overall survival (OS) for all 136 patients with PIK3CA
mutations and/or PTEN aberrations treated with PI3K/AKT/
mTOR inhibitors was 7.7 months (95% CI 5.6–9.8). There was
no difference among patients with PIK3CA mutations, PTEN
aberrations, or both PIK3CA mutations and PTEN aberrations
in median OS (7.5 months, 95% CI 4.3–10.7 versus 7.7 months,
95% CI 6.0–9.4 versus 14.9 months, 95% CI 6.3–23.5; p = 0.56).
Patients (n = 67) with PIK3CA mutations and/or PTEN aberra-
tions who received protocol-based experimental therapies other
than PI3K/AKT/mTOR inhibitors had a trend to longer medianOS
compared to patients (n = 136) with PIK3CA mutations and/or
PTEN aberrations treated with PI3K/AKT/mTOR-based thera-
pies (8.9 months, 95% CI 2.7–15.1 versus 7.7 months, 95% CI
5.6–9.8; p = 0.06). In addition, an analysis excluding patients
with colorectal cancer demonstrated that patients (n = 52) with
PIK3CA mutations and/or PTEN aberrations who received
protocol-based experimental therapies other than PI3K/AKT/
mTOR inhibitors had a similar median OS as patients (n = 111)
with PIK3CA mutations and/or PTEN aberrations treated with
PI3K/AKT/mTOR-based therapies (7.1 months, 95% CI 2.3–
11.9 versus 7.7 months, 95% CI 5.5–9.9; p = 0.17).
Also, there was no difference in median OS between patients
(n = 25) with PIK3CA mutations and/or PTEN aberrations and
colorectal cancer treated with PI3K/AKT/mTOR inhibitors
compared to patients (n = 111)with other histologies (8.9months,
Table 3. Multicovariate Models
Outcome Measure Variable OR/HRa 95% CI p Value
PR (RECIST) colorectal cancer versus other cancers Not calculatedb Not calculatedb
combination therapies versus single agents 5.31 1.16–24.25 0.03
more than three prior versus three or fewer prior therapies 0.67 0.25–1.82 0.43
PR and SDR 6 months
(RECIST)
colorectal cancer versus other cancers 0.13 0.02–1.07 0.06
combination therapies versus single agents 4.99 1.39–17.89 0.01
more than three prior versus three or fewer prior therapies 0.47 0.18–1.19 0.11
PFS colorectal cancer versus other cancers 1.59 0.98–2.59 0.06
combination therapies versus single agents 0.54 0.35–0.82 0.004
OS colorectal cancer versus other cancers 1.34 0.79–2.26 0.28
combination therapies versus single agents 0.78 0.50–1.19 0.25
Multicovariate model for response/prolonged SD per RECIST (logistic regression), PFS (Cox regression), and OS (Cox regression) in patients (n = 136)
with PIK3CA mutations and/or PTEN aberrations treated with PI3K/AKT/mTOR inhibitors.
aOR was calculated for a PR and SDR 6 months. HR was calculated for PFS and OS.
bOR and 95% CI were not calculated because none of the patients with colorectal cancer attained a PR.95% CI 4.3–13.5 versus 7.7 months, 95% CI 5.4–9.9; p = 0.18).
Patients (n = 95) with PIK3CA mutations and/or PTEN aberra-
tions treated with combination therapies that included PI3K/
AKT/mTOR inhibitors had a similar median OS as patients
(n = 41) treated with single-agent PI3K/AKT/mTOR inhibitor-
based therapies (8.0 months, 95% CI 5.7–10.2 versus
7.5 months, 95% CI 4.1–10.9; p = 0.17). Finally, patients (n =
80) with PIK3CA mutations and/or PTEN aberrations who
received up to three prior therapies had a similar median OS
as patients (n = 56) who received more than three therapies
(7.4 months, 95% CI 4.7–10.1 versus 8.2 months, 95% CI 5.4–
11.0; p = 0.98) prior to treatment with PI3K/AKT/mTOR inhibitors.
Of the 109 patients with PIK3CA mutations and/or PTEN
aberrations treated with PI3K/AKT/mTOR inhibitors who had
tissue available for KRAS mutation testing, 26 patients with
PIK3CA mutations and/or PTEN aberrations and simultaneous
KRAS mutations in codon 12 or 13 had a similar median OS
compared to 83 patients with PIK3CA mutations and/or PTEN
aberrations without KRAS mutations in codon 12 or 13
(7.5 months, 95% CI 3.7–11.3 versus 8.2 months, 95% CI 4.5–
11.9; p = 0.25).
In 85 patients with PIK3CA mutations treated with PI3K/
AKT/mTOR inhibitors, 20 patients with a H1047R mutation
compared to patients with other PIK3CA mutations had a trend
to a longer median OS (10.0 months, 95% CI 1.9–18.1 versus
8.2 months, 4.2–12.2; p = 0.15).
Multicovariate Analysis
We created a multicovariate Cox regression model for 203
patients with PIK3CAmutations and/or PTEN aberrations, which
included 136 patients treated with PI3K/AKT/mTOR inhibitors
and 67 patients treated with other protocol-based therapies.
Thismodel included number of prior therapies (up to three versus
more than three), histology (colorectal versus others), type of
therapy (combination versus single agent), and treatment with
PI3K/AKT/mTOR inhibitors (yes versus no), which were either
close to significance on univariate analysis (data not shown) or
were anticipated to be important. None of the factors indepen-
dently predicted OS; however, patients treated with experi-
mental therapies other than PI3K/AKT/mTOR inhibitors had aCtrend toward a longer OS (HR 0.69, 95% CI 0.47–1.01; p =
0.06; Table 2).
In addition, a multicovariable Cox regression model in patients
with PIK3CA mutations or PTEN aberrations treated with PI3K/
AKT/mTOR inhibitors, which included histology (colorectal
versus others) and type of therapy (combination versus single
agent), demonstrated that none of the tested variables predicted
survival (Table 3). Similarly, in a separate multicovariable Cox
regression model with 109 patients tested for KRAS mutations,
which included histology (colorectal versus others), KRASmuta-
tion (codons 12 and 13 versus others), and type of therapy (com-
bination versus single agent), none of the tested variables
predicted survival.
DISCUSSION
In our study, we observed that PIK3CA mutations and/or PTEN
aberrations can be detected in 20% of patients with diverse
advanced cancers (Figure 1). In agreement with previous
reports, the most frequent PIK3CA mutations were E545K
(32.5%), E542K (20%) in the helical domain, and H1047R
(18%) in the kinase domain (Forbes et al., 2011; Janku et al.,
2012a). PTEN aberrations were mostly determined by loss of
staining on immunohistochemistry (95% of patients with PTEN
aberration), as only 5% of patients were tested for PTEN
mutations. Anecdotally, we noticed that PTEN mutations could
occasionally be detectedwithout the loss of staining on immuno-
histochemistry, which is in agreement with previous publications
(Cheung et al., 2011).
Our group and others showed that, in colorectal and gyne-
cological cancers,PIK3CAmutationsoftencoexistwithmutations
in the MAPK pathway such as KRAS and BRAFmutations, which
can abrogate response to PI3K/AKT/mTOR pathway inhibitors
(De Roock et al., 2010; Di Nicolantonio et al., 2010; Engelman
et al., 2008; Ihle et al., 2009; Janku et al., 2011a, 2012b). The
current studyconfirmspreclinical findingsdemonstrating thatmu-
tations in the MAPK pathway are associated with an attenuated
response rate to PI3K/AKT/mTOR inhibitors (Di Nicolantonio
et al., 2010; Engelman et al., 2008; Ihle et al., 2009). Furthermore,ell Reports 6, 377–387, January 30, 2014 ª2014 The Authors 383
Figure 5. Kaplan-Meier Plot for PFS
(A–C) Tick marks represent patients who were progression free at last follow
up and are censored at that point.
(A) Patients with PIK3CA mutations and/or PTEN aberrations treated with
combination therapies (yellow, n = 95) compared to patients treated with
single-agent therapies (blue, n = 41) had a longer median PFS (3.0 months,
95% CI 2.0–4.0 versus 1.8 months, 95% CI 1.6–2.0; p < 0.001).
(B) Patients with PIK3CA mutations and/or PTEN aberrations and simulta-
neous KRAS mutations in codon 12 or 13 (yellow) compared to patients
without KRAS mutations in codon 12 or 13 (blue) had a shorter median PFS
(1.8 months, 95% CI 1.6–2.0 versus 2.9 months, 95% CI 1.9–3.9; p = 0.004).
(C) Patients with an H1047R mutation (yellow) compared to patients with other
PIK3CA mutations (blue) had a longer median PFS (4.6 months, 95% CI 0.6–
8.6 versus 2 months, 95% CI 1.6–2.4; p = 0.03).aberrations in the PI3K/AKT/mTOR pathway often coexist with
aberrations in the MAPK pathway (De Roock et al., 2010; Janku
et al., 2011a). Indeed, PIK3CA mutations compared to WT
PIK3CAwere associatedwith an increasedprevalenceof coexist-
ing KRASmutations (19% versus 9%; p < 0.001; Figure 2). Inter-
estingly, PTEN aberrations were not associated with KRAS
mutations.384 Cell Reports 6, 377–387, January 30, 2014 ª2014 The AuthorsOverall, 44% (136/309) of heavily pretreated patients with
PIK3CAmutations or PTEN aberrations were treated with thera-
pies that included PI3K/AKT/mTOR inhibitors, which consisted
of rapalog-based regimens in 76% of them. The overall PR
rate was 18% (in addition, 7% achieved SD R 6 months; Fig-
ure 4), and this response rate compared favorably to a CR/PR
rate of 6% in patients without known PIK3CA mutations or
PTEN aberrations, who received treatment on the same proto-
cols (p < 0.001), and also to a PR rate of 4% in patients with
PIK3CA mutations and/or PTEN aberrations, who received
experimental therapies without PI3K/AKT/mTOR inhibitors (p =
0.008). In addition, treatment with PI3K/AKT/mTOR inhibitors
was found, in multicovariate analysis, to be an independent
predictive factor for a PR in patients (n = 203) with PIK3CA
mutations and/or PTEN aberrations treated with PI3K/AKT/
mTOR or other protocol-based therapies (OR 4.34, 95% CI
1.23–15.24; p = 0.02; Table 2), although it did not translate to pro-
longed PFS and OS.
There was no difference in PR rate (18% versus 20% versus
11%; p = 0.83), PFS (2.3 months versus 3.5 months versus
2.8 months; p = 0.83), and OS (7.5 months versus 7.7 months
versus 14.9 months; p = 0.56) on therapies with PI3K/AKT/
mTOR inhibitors between patients with PIK3CA mutations,
PTEN aberrations, or both, respectively. None of the patients
with PIK3CA mutations and/or PTEN aberrations and colorectal
cancer attained a PR on therapies with PI3K/AKT/mTOR inhibi-
tors compared to 23% of patients with other histologies (p =
0.008). Additionally, patients with colorectal cancer demon-
strated a shorter PFS compared to other histologies treated
with PI3K/AKT/mTOR inhibitors (1.8 months versus 2.8 months;
p = 0.003), which suggests that specific molecular aberrations
can have different biological and therapeutic consequences in
different disease types. Alternatively, it is plausible that aberra-
tions in the PI3K/AKT/mTOR axis more frequently coexist with
MAPK aberrations in colorectal cancer than in other histologies
(Janku et al., 2011a). Interestingly, Dienstmann et al. (2012)
demonstrated that only 1 (2%) of 42 patients with colorectal
cancer and PIK3CA mutations (n = 10) or PTEN loss (n = 32)
responded to PI3K pathway inhibitors. Another example
showing how the same mutation can have diverse implications
in different contexts is the BRAF V600Emutation, which is highly
predictive of response, PFS, and OS to BRAF inhibitors in mela-
noma but not in colorectal cancer (El-Osta et al., 2011; Flaherty
et al., 2010; S. Kopetz et al., 2010, Am. Soc. Clin. Oncol.,
abstract). In addition, HER2 amplification or overexpression
predicts PFS and OS when HER2 targeting therapies are used
for treatment in breast and gastric cancers, but not necessarily
in other cancers (Bang et al., 2010; Galsky et al., 2012). On the
other hand, for many malignancies, the presence of molecular
aberrations predicts response across several histologies, with
BRAF mutations predicting response to BRAF inhibitors in
melanoma, papillary thyroid cancer, and hairy cell leukemia (Die-
trich et al., 2012; Falchook et al., 2012). Similarly, in our study, in
patients with PIK3CA mutations and/or PTEN aberrations,
responses to PI3K/AKT/mTOR inhibitors were seen across all
histologies except for colorectal cancer.
Patients with PIK3CA mutations and/or PTEN aber-
rations treated with combination therapies that included
PI3K/AKT/mTOR inhibitors had higher PR rates (24%versus 5%;
p = 0.007) and longer PFS (3.0 months versus 1.8 months; p <
0.001; Figure 5A) than patients treated with single-agent PI3K/
AKT/mTOR inhibitors. Combinations were also used frequently
in the WT PIK3CA group, and the PR/CR rate was significantly
lower, suggesting that factors other than the use of combinations
mediate response. In addition, the higher PR rate with com-
binations is not unexpected, as combinations have shown
more benefit in multiple preclinical models and clinical studies
(Engelman et al., 2008; Janku et al., 2012b; Wee et al., 2009).
Single-agent inhibition of the PI3K/AKT/mTOR pathway is often
cytostatic rather than cytotoxic, and activation of compensatory
pathways by other molecular aberrations can lead to therapeutic
resistance (Faber et al., 2009; Wee et al., 2009). Alternatively,
sensitivity to single-agent inhibition can be dependent on BIM
(a proapoptotic Bcl-2 family protein) levels; low levels of BIM
preclude cancer cells from undergoing apoptosis in response
to targeted therapy (Faber et al., 2011; Ng et al., 2012). In addi-
tion, the efficacy of single-agent therapies can be compromised
because of underlying tumor heterogeneity, which can poten-
tially be overcome with combination therapies (Gerlinger et al.,
2012).
In agreement with the hypothesis that KRAS mutations can
induce resistance to PI3K/AKT/mTOR pathway inhibitors, we
observed that patients with PIK3CA mutations and/or PTEN
aberrations and simultaneous KRAS mutations in codon 12 or
13 compared to patients with PIK3CA mutations and without
KRAS mutations in codon 12 and 13 had a significantly lower
PR rate (4% versus 24%; p = 0.023) and shorter median PFS
(1.8 months versus 2.9 months; p = 0.004; Figure 5B); however,
these findings should be interpreted with caution since the
presence of KRAS mutations did not reach significance as an
independent factor predicting response or lack thereof in multi-
covariate analysis.
Preclinical data and our preliminary clinical data suggested
that the PIK3CA H1047R mutation compared to others can be
a stronger driver for tumor development and can be associated
with better efficacy in PI3K targeting (Bader et al., 2006; Janku
et al., 2013; Ross et al., 2013; D.J. Matthews et al., 2011, Am.
Assoc. Cancer Res., abstract). We observed that patients with
an H1047R mutation compared to patients with other PIK3CA
mutations had a higher PR rate (35% versus 12%; p = 0.039),
higher SD R 6 months/PR rate (45% versus 17%; p = 0.016),
and longer PFS (4.6 months versus 2 months; p = 0.03;
Figure 5C).
Our study has several important limitations. First, although
multicovariate analysis showed that the only independent factor
predicting response in patients with tumors and PIK3CA
mutations and/or PTEN aberrations was treatment with PI3K/
AKT/mTOR inhibitors, our analysis was performed retrospec-
tively and it was not randomized. Second, we included diverse
cancers; however, the latter could suggest that the conclusions
are generalizable across histologies. Third, molecular analysis
was usually performed on archival tumor tissue, which was
obtained at a variety of time points in relationship to administra-
tion of treatment. This study therefore should be considered
hypothesis generating, and prospective validation of key find-
ings will be needed.CIn conclusion, we have demonstrated that screening for
PIK3CA mutations, PTEN aberrations, and MAPK mutations
can identify a subset of patients with advanced, heavily pre-
treated cancers who respond to therapeutic targeting with
PI3K/AKT/mTOR pathway inhibitors. Patients with H1047R
mutations did especially well with an SD R 6 months/PR rate
of 75%, albeit with only a small number of patients treated
(n = 20). The observed PR rate and even more so PFS falls short
compared to some other targeted therapies such as EGFR
inhibitors in EGFR mutant non-small-cell lung cancer, BRAF
inhibitors in BRAF mutant melanoma, or imatinib in BCR-ABL
rearranged CML (Druker et al., 2001; Falchook et al., 2012;
Flaherty et al., 2010; Lynch et al., 2004.) This can be partially
explained by the presence of simultaneous KRAS mutations;
however, other factors such as insufficient target inhibition,
activating feedback loops, pathway circumvention, or alternate
mechanism of pathway activation can be involved. Importantly,
in the case of CML, treatment early in the disease was key to
improving PFS and OS; when imatinib is given to patients with
blast transformation, a disease stage that can be viewed as
analogous to metastatic disease in solid tumors, only a minority
of patients respond and survival benefit is measured in months
rather than years (Westin and Kurzrock, 2012). However, even
with these limitations, drugs targeting the PI3K/AKT/mTOR
pathway still make an impact, with a PR rate tripled (18% versus
6%) in patients with PIK3CA mutations or PTEN aberrations
compared to patients with no aberrations in PIK3CA or PTEN.
Nevertheless, the treatment with a PI3K/AKT/mTOR pathway
inhibitor may not be sufficient and, therefore, the improvement
in the PR rate does not translate to prolonged PFS. Collectively,
these observations warrant further prospective investigation,
especially since many PI3K/AKT/mTOR inhibitors are now
entering the clinical arena.EXPERIMENTAL PROCEDURES
Patients
PIK3CA mutations and PTEN aberrations were retrospectively investigated
in consecutive patients with advanced tumors, and available tissue was
referred to the Clinical Center for Targeted Therapy at MD Anderson for
clinical trials of targeted therapeutic agents starting in October 2008. The
registration of patients in the database, pathology assessment, and mutation
analysis were performed at MD Anderson. The study and all treatments were
conducted in accordance with MD Anderson Institutional Review Board
guidelines.
Tumor Tissue Analyses
PIK3CA mutations and PTEN aberrations were investigated in archival
formalin-fixed, paraffin-embedded tissue blocks obtained from diagnostic
and/or therapeutic procedures from primary or metastatic sites. All histologies
were centrally reviewed at MD Anderson. Mutation testing was performed in
the Clinical Laboratory Improvement Amendment-certified Molecular Diag-
nostic Laboratory within the Division of Pathology and Laboratory Medicine
at MD Anderson. DNA was extracted from microdissected paraffin-
embedded tumor sections and analyzed using a PCR-based DNA sequencing
method for PIK3CA mutations in codons 532–554 of exon 9 (helical domain)
and codons 1011–1062 of exon 20 (kinase domain). This analysis encom-
passed the mutation hot spot regions of the PIK3CA proto-oncogene denoted
by Sanger sequencing, following amplification of 276 bp and 198 bp ampli-
cons, respectively, utilizing primers designed by the MD Anderson Molecular
Diagnostics Laboratory. Since January 2011, the assay has been changed toell Reports 6, 377–387, January 30, 2014 ª2014 The Authors 385
mass spectrometric detection (Sequenom MassARRAY) to screen for the
mutational hot spots in exon 1 (Q60K, R88Q, E110K, and K111N), exon 4
(N345K), exon 6 (S405S), exon 7 (E418K, C420R, and E453K), exon 9
(P539R, E542 [bases 1 and 2], E545 [all three bases], and Q546 [bases 1
and 2]), exon 18 (F909L), and exon 20 (Y1021 [bases 1 and 2], T1025
[base 1], M1043I, M1043V, A1046V, H1047Y, H1047R, H1047L, and
G1049R). The mutations identified during the initial screening were confirmed
by Sanger sequencing assay. The lower limit of detection is approximately
10%. PTEN mutations were detected in exons 1–9 using PCR-based DNA
sequencing and the lower limit of detection was approximately 20%. PTEN
expression was tested with immunohistochemistry using the monoclonal
mouse anti-human antibody clone 6H2.1 (Dako), and complete loss of stain-
ing was classified as PTEN loss. Whenever possible, additional MAPK muta-
tion analyses for KRAS, NRAS codons 12, 13, and 61 mutations of exons 1
and 2, and BRAF mutations in exon 15 were carried out using PCR-based
DNA sequencing (Zuo et al., 2009). The lower limit of detection was approxi-
mately 20%.
Treatment and Evaluation
Assignment to a clinical trial was determined after clinical, laboratory, and
pathologic data from all available patient records were reviewed. Consecutive
patients who had tumor tissue that could be tested or had been tested with
underlying PIK3CA mutations and/or a PTEN aberration were enrolled, when-
ever possible, in clinical trials that included inhibitors of the PI3K/AKT/mTOR
pathway. Treatment continued until disease progression or unacceptable
toxicity occurred. Treatment was carried out according to the specific requi-
sites in the treatment protocols selected.
Assessments, including history, physical examination, and laboratory
evaluations, were performed as specified in each protocol, typically before
the initiation of therapy, weekly during the first cycle and then, at a minimum,
at the beginning of each new treatment cycle. Efficacy was assessed from
computed tomography scans and/or MRI at baseline before treatment initia-
tion and then approximately every two cycles (6—8 weeks). All radiographs
were read in the Department of Radiology and reviewed in the Department
of Investigational Cancer Therapeutics tumor measurement clinic at MD
Anderson. Responses were categorized per Response Evaluation Criteria in
Solid Tumors (RECIST) and were reported as best response (Therasse
et al., 2000). In brief, a CR was defined as the disappearance of all measurable
and nonmeasurable disease; PR was defined as at least a 30% decrease in
the sum of the longest diameter of measurable target lesions; progressive
disease (PD) was defined as at least a 20% increase in the sum of the longest
diameter of measurable target lesions, unequivocal progression of a
nontarget lesion, or the appearance of a new lesion; and SD was defined as
neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify
for PD.
Statistical Analysis
Statistics were verified by our statistician (J.J.L.). Two-way contingency tables
were formed to summarize the relationship between two categorical variables.
Fisher’s exact test was used to assess the association among categorical
variables and mutation status. Wilcoxon rank-sum test was applied to assess
the association among continuous variables and mutation status. Multico-
variable logistic regression analysis was applied to identify the multiple pre-
dictors associated with the response outcomes and number of prior therapies,
histology, type of therapy, PIK3CA mutations, PTEN aberrations and MAPK
(KRAS, NRAS, and BRAF) mutations, and others. PFS was defined as the
time interval from the start of therapy to the first observation of disease
progression or death, whichever occurred first. Patients alive and without
disease progression were censored at the last follow-up date. OS was defined
as the time interval from the start of therapy to the date of death or the date of
last follow up, whichever occurred first. OS and PFS were estimated using the
method of Kaplan andMeier (1958) and were compared among the subgroups
of patients using a log-rank test. Cox proportional hazards regression models
were fit to assess the association between patient characteristics and PFS or
OS (Cox, 1972). All tests were two sided, and P values less than 0.05 were
considered statistically significant. All statistical analyses were carried out us-
ing SPSS 19 computer software (SPSS).386 Cell Reports 6, 377–387, January 30, 2014 ª2014 The AuthorsSUPPLEMENTAL INFORMATION
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